Jay Steingrub to Risk Assessment
This is a "connection" page, showing publications Jay Steingrub has written about Risk Assessment.
Connection Strength
0.072
-
Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, Shapiro NI, Ginde AA, Douin DJ, Prekker ME, Brown SM, Peltan ID, Gong MN, Mohamed A, Khan A, Exline MC, Files DC, Gibbs KW, Stubblefield WB, Casey JD, Rice TW, Grijalva CG, Hager DN, Shehu A, Qadir N, Chang SY, Wilson JG, Gaglani M, Murthy K, Calhoun N, Monto AS, Martin ET, Malani A, Zimmerman RK, Silveira FP, Middleton DB, Zhu Y, Wyatt D, Stephenson M, Baughman A, Womack KN, Hart KW, Kobayashi M, Verani JR, Patel MM. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged =65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):674-679.
Score: 0.027
-
Stefan MS, Priya A, Pekow PS, Steingrub JS, Hill NS, Lagu T, Raghunathan K, Bhat AG, Lindenauer PK. A scoring system derived from electronic health records to identify patients at high risk for noninvasive ventilation failure. BMC Pulm Med. 2021 Feb 05; 21(1):52.
Score: 0.026
-
Mitchell SC, Steingrub J. The changing clinical trials scene: the role of the IRB. IRB. 1988 Jul-Aug; 10(4):1-5.
Score: 0.011
-
L?pez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004 Jan; 32(1):21-30.
Score: 0.008